Skip to Content


Active Substance: colestilan
Common Name: colestilan
ATC Code: V03AE
Marketing Authorisation Holder: Mitsubishi Pharma Europe Ltd
Active Substance: colestilan
Status: Withdrawn
Authorisation Date: 2013-01-21
Therapeutic Area: Hyperphosphatemia
Pharmacotherapeutic Group: Drugs for treatment of hyperkalaemia and hyperphosphataemia

Therapeutic Indication

Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.

The marketing authorisation for BindRen has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.